<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124759</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20130459H</org_study_id>
    <secondary_id>IRB #20130458H</secondary_id>
    <nct_id>NCT02124759</nct_id>
  </id_info>
  <brief_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)</brief_title>
  <acronym>MicroB1</acronym>
  <official_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of high fat consumption on the
      intestinal microbiome, metabolic endotoxemia, and insulin action, in lean normal glucose
      tolerant subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will test the hypothesis that a high fat diet given to lean, normal glucose tolerant
      subjects will modify gut microbiome composition and enhance intestinal permeability, which
      will increase plasma LPS concentration, induce an inflammatory response in peripheral tissues
      (skeletal muscle), and impair insulin signaling and sensitivity. Also we will test the
      hypothesis that the inflammatory response and insulin resistance caused by high fat ingestion
      can be ameliorated by administering

        -  a synbiotic (Bifidobacterium longum R0175 and oligofructose) which protects the
           intestinal epithelial barrier and decreases intestinal translocation of LPS; and

        -  sevelamer, an agent which sequesters lipopolysaccharide (LPS) in the gastrointestinal
           tract limiting its translocation into the circulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>At day 28th after put the intervention.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma endotoxin levels</measure>
    <time_frame>At baseline, on day 3, and 28 of the intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut permeability</measure>
    <time_frame>on Day 24 of the intervention.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>High fat diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The high fat diet will provide 60% of energy from fat (of which 50% from saturated fat), 15% of energy as CHO and 25% from protein.
subjects will be randomized to receive, in a double-blind fashion
placebo, maltodextrin, 6 g three times a day
synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]
sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fat diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The low fat diet will provide 55% of energy from CHO, 20% from fat, and 25% from protein.
subjects will be randomized to receive, in a double-blind fashion
placebo, maltodextrin, 6 g three times a day
synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]
sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <description>1.6 g sevelamer + 4.4 g maltodextrin three times a day</description>
    <arm_group_label>High fat diet</arm_group_label>
    <arm_group_label>Low fat diet</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.</description>
    <arm_group_label>High fat diet</arm_group_label>
    <arm_group_label>Low fat diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>This is a control group. Maltodextrin, 6 g three times a day</description>
    <arm_group_label>High fat diet</arm_group_label>
    <arm_group_label>Low fat diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders. All races and ethnic groups.

          -  Premenopausal women in the follicular phase, non-lactating, and with a negative
             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone
             replacement for ≥6 months.

          -  Hematocrit (HCT)≥ 34%, serum creatinine ≤ 1.4 mg/dl, and normal serum electrolytes,
             urinalysis, and coagulation tests. Liver function tests (LFTs) up to 2 times normal.

          -  Stable body weight (±2%) for ≥ 3 months

          -  Two or less sessions of strenuous exercise/wk for last 6 months.

        Exclusion Criteria:

          -  Presence of diabetes or impaired glucose tolerance based on ADA criteria.

          -  Current treatment with drugs known to affect glucose and lipid homeostasis. If the
             subject has been on a stable dose for the past 3 months, the following agents will be
             permitted: calcium channel blockers, β-blockers, ACE inhibitors, angiotensin receptor
             blockers, and statins

          -  History of allergy to sevelamer.

          -  History of Non-steroidal anti-inflammatory drugs or systemic steroid use for more than
             a week within 3 months.

          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and
             clopidogrel will be permitted if these can be held for seven days prior to the biopsy
             in accordance with the primary physician.

          -  Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG)
             within 3 months.

          -  History of heart disease (New York Heart Classification greater than grade II; more
             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,
             pulmonary disease, smokers.

          -  Poorly controlled blood pressure (systolic BP&gt;170, diastolic BP&gt;95 mmHg).

          -  Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and psychiatric
             disease.

          -  History of gastrointestinal surgery or gastrointestinal obstruction within two years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Musi, MD.</last_name>
    <phone>210-630-5001</phone>
    <email>Musi@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauri Che Kelly, RN.</last_name>
    <phone>210-617-5300</phone>
    <phone_ext>14731</phone_ext>
    <email>che@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital, STVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Musi, MD.</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>15197</phone_ext>
      <email>Musi@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauri Che Kelly, RN</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>14731</phone_ext>
      <email>che@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Musi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Nicolas Musi</investigator_full_name>
    <investigator_title>Nicolas Musi, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

